All In Biotech

Investigational drug · Phase 3

PD-1 monoclonal antibody

Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma.

Phase 3

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

9

9 still active

All registered trials

1,502

Any phase or sponsor naming "PD-1 monoclonal antibody"

First trial start

2023

Nov 16, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "PD-1 monoclonal antibody", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Nasopharyngeal Carcinoma (NPC)
  • Non-small Cell Lung Cancer
  • Nasopharyngeal Carcinoma
  • Solid Tumor
  • HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
  • Triple-negative Breast Cancer
  • Extensive-stage Small-cell Lung Cancer
  • Esophageal Cancer
  • Gastric Cancer
  • Colorectal Cancer

Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "PD-1 monoclonal antibody" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 609 on PubMed

Also in development for Nasopharyngeal Carcinoma (NPC)

  • BL-M08D1Phase 26 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Solid Tumors, Gastrointestinal Tumors, Diffuse Large B-Cell Lymphoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.